Skip to main content

Table 2 Interobserver agreement on axillary staging with FDG-PET/CT in supine or prone position

From: [18F]FDG-PET/CT in prone compared to supine position for optimal axillary staging and treatment in clinically node-positive breast cancer patients with neoadjuvant systemic therapy

  Axillary staging Agreement
Observer 1 Observer 2 Original report Observers Kappa Obs. & report *Kappa
Supine PET/CT          0.80    0.78
 cALN<4 115 75% 107 70% 108 71% 105 69%   99 65%  
 cALN≥4 38 25% 46 30% 45 29% 36 24%   34 22%  
 Total 153 100% 153 100% 153 100% 141 92%   133 87%  
Prone PET/CT          0.67    0.74
 cALN<4 116 76% 96 63% 108 71% 95 62%   93 61%  
 cALN≥4 37 24% 57 37% 45 29% 36 24%   35 23%  
 Total 153 100% 153 100% 153 100% 131 86%   128 84%  
  1. Data are N, %.*Fleiss kappa. Original report staging at time of treatment including both supine and prone FDG-PET/CT scans
  2. cALN<4 less than four FDG-positive axillary lymph nodes, cALN4 more than four FDG-positive axillary lymph nodes